ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of lymphoma called classic Hodgkin lymphoma.
- Your lymphoma came back or didn't get better after only one past chemotherapy treatment (which included doxorubicin).
- You have at least one spot of lymphoma that shows up on a PET/CT scan and is big enough to measure (see description).
- You have not had a stem cell transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy for people with newly diagnosed Hodgkin lymphoma who are too frail for standard treatment. The goal is to find a safer, effective option for patients who are older or have other health issues.
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding a type of immune-boosting drug (called checkpoint inhibitor immunotherapy) after high-dose chemotherapy and stem cell transplant helps people with Hodgkin lymphoma that has returned or didn't respond to initial treatment. The goal is to see if this combination works better than chemotherapy and transplant alone.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Hear when a new Hodgkin Lymphoma, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.